J&J halts Doribax pneumonia trial on death rate; Jazz looks for 40% rise in Xyrem sales;

@FiercePharma: Watson CEO does about-face, says Pfizer won't keep 40% of Lipitor market. $PFE's share was 41% on Dec. 24--Bloomberg. | Follow @FiercePharma

> Johnson & Johnson ($JNJ) stopped a pneumonia trial of its antibiotic Doribax, which is FDA-approved for abdominal and urinary infections, after more Doribax patients died. News

> Jazz Pharmaceuticals ($JAZZ) says it expects a larger profit this year, thanks to the completion of its Azur Pharma buyout and fast-growing sales of its narcolepsy drug Xyrem. Report

> Physicians Interactive Holdings attracted a $17 million investment from Merck's Global Health Innovation Fund to back key products comprising clinical reference tools, electronic drug sampling and interactive education. Release

> Norgine is laying off three dozen workers at a facility in Wales, or 9% of its local workforce, because of declining demand for products. Story

> Lens maker Essilor bought a majority stake of a lab based in California and inked deals in Africa and South America. Article

Biotech News

@FierceBiotech: Bloomberg: Amgen May Join Gilead as Biotechs Seek Acquisitions to Grow. Article | Follow @FierceBiotech

@JohnCFierce: Bloomberg piece makes spike in drug approvals a sign of underlying shift; Really? I'm not so sure. More | Follow @JohnCFierce

@RyanMFierce: BioDelivery Sciences ($BDSI) grabbed $30M upfront from Endo Pharma for license to pain drug. Release | Follow @RyanMFierce

@FierceMedDev: BBC News: Headache sufferer 'abandoned' after electrode treatment. Story | Follow @FierceMedDev

@MaureenFierce: J&J AIDS vaccine helps protect monkeys from virus in study. Item | Follow @MaureenFierce

> Exclusive: MIT's Langer, Farokhzad launch combination-med biotech. News

> Xoma axing 84 jobs to save dollars for lead drug. More

> BioDelivery Sciences shares spike on $180M pain drug deal with Endo Pharma. Article

> Amgen, big biotechs poised for big year of deals, analysts say. Story

And Finally... Weekend plans with the significant other? A new study found greater-than-previously-thought personality differences between males and females. Item

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.